PDCD1 and non-small cell lung carcinoma: Programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have presented encouraging results in cancers as one class of immune checkpoint inhibitors, including melanoma, bladder cancer as well as non-small cell lung cancer (6, 7).